Master Protocol to Assess the Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumours

Official Title

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumours

Summary:

This trial will evaluate the safety and efficacy of first time in human engineered T-cell therapies, in participants with advanced tumours.

Trial Description

Primary Outcome:

  • Substudy 1 and 2: Frequency of dose limiting toxicities (DLTs) according to severity.
  • Substudy 1 and 2:Frequency of adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI) according to severity
Secondary Outcome:
  • Substudy 1 and 2: Overall response rate (ORR)
  • Substudy 1 and 2: Duration of response (DOR)
  • Substudy 2: Progression free survival (PFS)
  • Substudy 2: Disease control rate (DCR)
  • Substudy 2: Time to response
  • Substudy 1 and 2: Maximum expansion/persistence (Cmax)
  • Substudy 1 and 2: Time to Cmax (Tmax)
  • Substudy 1 and 2: Area under the concentration/persistence time curve from zero to time t (AUC[0-t])
  • Substudy 1 and 2: Phenotype of transduced T cells
New York esophageal antigen-1 (NY-ESO-1) and LAGE-1a antigens are tumour-associated proteins that have been found in several tumour types. Clinical trials using adoptively transferred T-cells directed against NY-ESO-1 have shown objective responses. GSK3901961 and GSK3845097 are next generation engineered TCR T-cells, co-expressing the CD8α cell surface receptor, targeting NY-ESO-1, and co-expressing the dnTGF-βRII cell surface receptor, targeting NY-ESO-1, respectively to potentially improve function. This is a master protocol evaluating first time in human T-cell therapies. It will initially consist of two independent substudies, investigating GSK3901961 and GSK3845097 in HLA*A02+ participants with NYESO1+ previously treated advanced (metastatic or unresectable) synovial sarcoma (SS) and/or previously treated metastatic non-small cell lung cancer (NSCLC).

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society